An experimental Parkinson’s drug missed its primary goal in a mid-stage trial, Roche said, in what is the second setback this week for candidate treatments for the neurodegenerative condition.
Trending
- Winter Paralympics officially open, Russian athletes greeted with boos
- Just Formula E on steroids?
- Timothee Chalamet faces backlash from opera and ballet stars over ‘disrespectful’ comment
- FTSE 100 extends slide as Brent crude tops 90 dollars a barrel
- Korean stocks suffer worst crash ever as Iran war hits chipmakers
- International Women’s Day: Workplace equality needs action
- New Louvre director tasked with leading a beleaguered landmark out of decades of crisis
- BBC ‘profoundly regrets’ BAFTAs incident, says director general Tim Davie | Ents & Arts News
